Literature DB >> 19022858

Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis.

E J Burton1, R Barber, E B Mukaetova-Ladinska, J Robson, R H Perry, E Jaros, R N Kalaria, J T O'Brien.   

Abstract

The purpose of this study was to determine the diagnostic accuracy of medial temporal lobe atrophy (MTA) on MRI for distinguishing Alzheimer's disease from other dementias in autopsy confirmed cases, and to determine pathological correlates of MTA in Alzheimer's disease, dementia with Lewy bodies (DLB) and vascular cognitive impairment (VCI). We studied 46 individuals who had both antemortem MRI and an autopsy. Subjects were clinicopathologically classified as having Alzheimer's disease (n = 11), DLB (n = 23) or VCI (n = 12). MTA was rated visually using a standardized (Scheltens) scale blind to clinical or autopsy diagnosis. Neuropathological analysis included Braak staging as well as quantitative analysis of plaques, tangles and alpha-synuclein Lewy body-associated pathology in the hippocampus. Correlations between MTA and pathological measures were carried out using Spearman's rho, linear regression to assess the contributions of local pathologic changes to MTA. Receiver operator curve analysis was used to assess the diagnostic specificity of MTA for Alzheimer's disease among individuals with Alzheimer's disease, DLB and VCI. MTA was a highly accurate diagnostic marker for autopsy confirmed Alzheimer's disease (sensitivity of 91% and specificity of 94%) compared with DLB and VCI. Across the entire sample, correlations were observed between MTA and Braak stage (rho = 0.50, P < 0.001), per cent area of plaques in the hippocampus (rho = 0.37, P = 0.014) and per cent area of tangles in the hippocampus (rho = 0.49, P = 0.001). Linear regression showed Braak stage (P = 0.022) to be a significant predictor of MTA but not percent area of plaques (P = 0.375), percent area of tangles (P = 0.330) or percent area of Lewy bodies (P = 0.086). MTA on MRI had robust discriminatory power for distinguishing Alzheimer's disease from DLB and VCI in pathologically confirmed cases. Pathologically, it is more strongly related to tangle rather than plaque or Lewy body pathology in the temporal lobe. It may have utility as a means for stratifying samples in vivo on the basis of putative differences in pathology.

Entities:  

Mesh:

Year:  2008        PMID: 19022858     DOI: 10.1093/brain/awn298

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  123 in total

1.  Difficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder.

Authors:  Murray Grossman; Rachel G Gross; Peachie Moore; Michael Dreyfuss; Corey T McMillan; Philip A Cook; Sherry Ash; Andrew Siderowf
Journal:  Brain Lang       Date:  2011-09-29       Impact factor: 2.381

2.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

3.  Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease.

Authors:  Matthew Schrag; Andrew Crofton; Matthew Zabel; Arshad Jiffry; David Kirsch; April Dickson; Xiao Wen Mao; Harry V Vinters; Dylan W Domaille; Christopher J Chang; Wolff Kirsch
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.

Authors:  Akihiko Shiino; Toshiyuki Watanabe; Yoshitomo Shirakashi; Emi Kotani; Masahiro Yoshimura; Shigehiro Morikawa; Toshiro Inubushi; Ichiro Akiguchi
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-08       Impact factor: 6.200

5.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

6.  The organization of narrative discourse in Lewy body spectrum disorder.

Authors:  Sharon Ash; Corey McMillan; Rachel G Gross; Philip Cook; Brianna Morgan; Ashley Boller; Michael Dreyfuss; Andrew Siderowf; Murray Grossman
Journal:  Brain Lang       Date:  2011-10       Impact factor: 2.381

Review 7.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 8.  Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

9.  Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Tanis J Ferman; Bradley F Boeve; Stephen D Weigand; Scott Przybelski; Prashanthi Vemuri; Melissa E Murray; Melissa M Murray; Matthew L Senjem; Glenn E Smith; David S Knopman; Ronald C Petersen; Clifford R Jack; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.